1. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart FailureClinical Perspective
by A. Rogier van der Velde, Lars Gullestad, Thor Ueland, Pål Aukrust, Yu Guo, Aram Adourian, Pieter Muntendam, Dirk J. van Veldhuisen, and Rudolf A. de Boer
Circ Heart Fail
Volume 6(2):
March 19, 2013
Copyright © American Heart Association, Inc. All rights reserved.

2. A, Cumulative incidence curves for mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by categorical change between baseline and 3 months.
A, Cumulative incidence curves for mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by categorical change between baseline and 3 months. Log-rank P< B, Cumulative incidence curves for mortality and HF hospitalization in Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) by categorical change between baseline and 6 months. Log-rank P<0.001.
A. Rogier van der Velde et al. Circ Heart Fail. 2013;6:
Copyright © American Heart Association, Inc. All rights reserved.

3. A, Cumulative incidence curves for cumulative mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by galectin-3 percentage change from baseline, adjusted for baseline galectin-3 value.
A, Cumulative incidence curves for cumulative mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by galectin-3 percentage change from baseline, adjusted for baseline galectin-3 value. Log-rank P= B, Cumulative incidence curves for cumulative mortality and HF hospitalization in Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) by galectin-3 percentage change from baseline, adjusted for baseline galectin-3 value. Log-rank P=0.029.
A. Rogier van der Velde et al. Circ Heart Fail. 2013;6:
Copyright © American Heart Association, Inc. All rights reserved.